MD1179Y - Метод лечения трофических язв - Google Patents
Метод лечения трофических язв Download PDFInfo
- Publication number
- MD1179Y MD1179Y MDS20170043A MDS20170043A MD1179Y MD 1179 Y MD1179 Y MD 1179Y MD S20170043 A MDS20170043 A MD S20170043A MD S20170043 A MDS20170043 A MD S20170043A MD 1179 Y MD1179 Y MD 1179Y
- Authority
- MD
- Moldova
- Prior art keywords
- wound
- blood
- patient
- suspension
- fibrin clot
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 41
- 208000025865 Ulcer Diseases 0.000 title claims abstract description 12
- 231100000397 ulcer Toxicity 0.000 title claims abstract description 12
- 230000001228 trophic effect Effects 0.000 title claims abstract description 10
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 30
- 102000009123 Fibrin Human genes 0.000 claims abstract description 19
- 108010073385 Fibrin Proteins 0.000 claims abstract description 19
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229950003499 fibrin Drugs 0.000 claims abstract description 19
- 210000004369 blood Anatomy 0.000 claims abstract description 17
- 239000008280 blood Substances 0.000 claims abstract description 17
- 239000000725 suspension Substances 0.000 claims abstract description 10
- 210000005087 mononuclear cell Anatomy 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims abstract description 7
- 238000001356 surgical procedure Methods 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 2
- 206010052428 Wound Diseases 0.000 description 26
- 230000008569 process Effects 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 208000008960 Diabetic foot Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000012190 activator Substances 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000001338 necrotic effect Effects 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- LFHSNLRTGGKKRT-UHFFFAOYSA-N 3-iodopyran-2-one Chemical compound IC1=CC=COC1=O LFHSNLRTGGKKRT-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- -1 TC 199 Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000123 anti-resoprtive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- DRFILBXQKYDTFW-JIWRMXRASA-L disodium;2-[[(2r)-2-[[(4s)-4-amino-4-carboxybutanoyl]amino]-3-[[(2r)-2-[[(4s)-4-amino-4-carboxybutanoyl]amino]-3-(carboxylatomethylamino)-3-oxopropyl]disulfanyl]propanoyl]amino]acetate Chemical compound [Na+].[Na+].OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC([O-])=O)CSSC[C@@H](C(=O)NCC([O-])=O)NC(=O)CC[C@H](N)C(O)=O DRFILBXQKYDTFW-JIWRMXRASA-L 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 108010068227 glutoxim Proteins 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Изобретение относится к медицине, в частности к гнойной хирургии и может быть использовано для лечения трофических язв.Метод состоит в том, что за 24...48 часов до лечения отделяют суспензию мононуклеарных клеток из крови пациента, содержащей 3×107/мл клеток, также от пациента за 2...3 часа до первой процедуры проводят забор 30...40 мл крови, которую центрифугируют в течение 8...12 мин с 3000...3500 об./мин с получением фибринового сгустка обогащенного тромбоцитами, суспензию вводят подкожно вокруг раны, на расстоянии 1 см от ее краев, в количестве 5...15 мл, после чего на рану применяют сгусток фибрина, процедура повторяется через каждые 4 дня, а курс лечения составляет 8...10 процедур.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20170043A MD1179Z (ru) | 2017-03-29 | 2017-03-29 | Метод лечения трофических язв |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20170043A MD1179Z (ru) | 2017-03-29 | 2017-03-29 | Метод лечения трофических язв |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD1179Y true MD1179Y (ru) | 2017-08-31 |
| MD1179Z MD1179Z (ru) | 2018-03-31 |
Family
ID=59759581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20170043A MD1179Z (ru) | 2017-03-29 | 2017-03-29 | Метод лечения трофических язв |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD1179Z (ru) |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU589983A1 (ru) * | 1974-07-16 | 1978-01-30 | Харьковский Научно-Исследовательский Институт Протезирования,Ортопедии И Травмотологии Им.Проф.М.И. Ситенко | Способ лечени трофических зв и длительно не заживающих ран |
| SU724141A1 (ru) * | 1977-07-04 | 1980-03-30 | Ростовский государственный медицинский институт | Средство дл лечени трофических зв |
| SU1118373A1 (ru) * | 1982-09-14 | 1984-10-15 | Московский Ордена Трудового Красного Знамени Медицинский Стоматологический Институт Им.Н.А.Семашко | Способ лечени трофических зв и длительно незаживающих ран |
| SU1263261A1 (ru) * | 1982-11-18 | 1986-10-15 | Zhukov Boris N | Способ лечени трофических зв |
| SU1219097A1 (ru) * | 1984-04-28 | 1986-03-23 | 1-Й Московский Ордена Ленина И Ордена Трудового Красного Знамени Медицинский Институт Им.И.М.Сеченова | Способ лечени трофических зв |
| SU1287869A1 (ru) * | 1985-04-23 | 1987-02-07 | Казанский государственный медицинский институт им.С.В.Курашова | Способ лечени больных с трофическими звами голени |
| SU1450831A1 (ru) * | 1986-12-03 | 1989-01-15 | Ленинградский Научно-Исследовательский Институт Скорой Помощи Им.Проф.И.И.Джанелидзе | Способ лечени трофических зв |
| SU1718947A1 (ru) * | 1987-01-06 | 1992-03-15 | Самарский медицинский институт им.Д.И.Ульянова | Способ лечени трофических зв и длительно незаживающих ран |
| SU1528468A1 (ru) * | 1987-02-02 | 1989-12-15 | Харьковский Научно-Исследовательский Институт Ортопедии И Травматологии Им.Проф.М.И.Ситенко | Способ кожной пластики при трофических звах и устройство дл его осуществлени |
| MD985G2 (ru) * | 1995-03-10 | 2000-02-29 | СПАТАРЕНКО Афанасий | Способ лечения ожогов и трофических язв |
| MD742C2 (ru) * | 1995-11-16 | 1998-02-28 | Ion Grudzitchii | Средство с регенеративной активностью |
| MD1052G2 (ru) * | 1998-02-18 | 1999-04-30 | Георге КУШНИР | Метод иммунотерапии Кушнира |
| RU2144831C1 (ru) * | 1998-11-02 | 2000-01-27 | Дальневосточный государственный медицинский университет | Способ лечения синдрома диабетической стопы |
| RU2184551C2 (ru) * | 1999-12-31 | 2002-07-10 | Лопатин Сергей Вячеславович | Способ лечения деструктивных форм диабетической стопы |
| MD1585G2 (ru) * | 2000-05-24 | 2001-07-31 | CIOBANU Pavel | Биостимуллирующее средство |
| RU2228204C2 (ru) * | 2002-04-15 | 2004-05-10 | Научно-исследовательский институт клинической и экспериментальной лимфологии СО РАМН | Способ лечения трофических язв на фоне синдрома диабетической стопы |
| MD2229G2 (ru) * | 2003-04-18 | 2004-02-29 | Мария ДАНУ | Метод лечения трофических язв голени на фоне хронической венозной недостаточности нижних конечностей |
| MD3076G2 (ru) * | 2004-11-09 | 2007-01-31 | Валериу РУДИК | Метод лечения гнойно-некротических ран у больных с диабетической стопой |
| MD2933G2 (ru) * | 2005-06-23 | 2006-08-31 | Виктор ГИКАВЫЙ | Метод лечения поражений кожи |
| RU2322247C1 (ru) * | 2006-06-16 | 2008-04-20 | Нефедов Виктор Иванович | Способ лечения язвенных дефектов при синдроме диабетической стопы |
| RU2359624C1 (ru) * | 2008-03-06 | 2009-06-27 | Шамиль Арифулович Тенчурин | Способ лечения трофических язв при диабетической стопе |
| MD4197C1 (ru) * | 2012-10-22 | 2013-09-30 | Мария ДАНУ | Метод лечения трофических язв |
| MD696Z (ru) * | 2013-03-26 | 2014-12-31 | Адриан КУШНИР | Метод лечения осложнений диабетической стопы |
-
2017
- 2017-03-29 MD MDS20170043A patent/MD1179Z/ru not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MD1179Z (ru) | 2018-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240415941A1 (en) | Process, Tube And Device For The Preparation Of Wound Healant Composition | |
| US5165938A (en) | Wound healing agents derived from platelets | |
| FI85219B (fi) | Foerfarande foer framstaellning av ett fraon blodplaettar loesgjort material. | |
| US5178883A (en) | Method for promoting hair growth | |
| US20040197319A1 (en) | Wound healing composition derived from low platelet concentration plasma | |
| WO2008022651A1 (en) | Process and device for the preparation of platelet rich plasma for extemporaneous use and combination thereof with skin and bone cells | |
| KR20010071577A (ko) | 혈소판이 풍부한 개선된 상처 치유제 | |
| US20030007957A1 (en) | Novel wound healing composition not containing bovine-derived activating reagents | |
| EP0453498A1 (en) | Method of promoting hair growth by applying a blood platelet extract | |
| CN110664735A (zh) | 一种富血小板凝胶及其制备方法 | |
| US20030152639A1 (en) | Novel wound healing composition not containing bovine-derived activating reagents | |
| EP3749336B1 (en) | Wound treatment gel obtainable by combining platelet rich plasma with autologously derived thrombin | |
| AU768543B2 (en) | Improved enriched platelet wound healant | |
| RU2543344C2 (ru) | Способ лечения трофических язв | |
| RU2616239C2 (ru) | Способ лечения эрозивно-язвенных поражений кожи | |
| MD1179Y (ru) | Метод лечения трофических язв | |
| RU2657806C2 (ru) | Способ регионального лечения трофической язвы | |
| WO2017082441A1 (ko) | 활성화된 혈소판 풍부 혈장을 유효성분으로 포함하는 동물의 창상 치료용 수의학적 조성물 | |
| Dubey et al. | The Efficacy of Local Autologous Platelet-Rich Plasma Prepared by Single and Double Spin Methods in the Treatment of Chronic Ulcer | |
| JP7309872B2 (ja) | 傷痍治療用医薬組成物 | |
| RU2847956C1 (ru) | Способ лечения инфицированных труднозаживающих ран с применением обогащённой тромбоцитами плазмы (PRP) | |
| Shehata et al. | Assessment of platelet rich plasma (PRP) therapy in prevention of chronic wound complications | |
| JPH0720873B2 (ja) | 創傷治癒剤 | |
| MD696Z (ru) | Метод лечения осложнений диабетической стопы | |
| MD1407Z (ru) | Метод лечения наружных кишечных свищей |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued | ||
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) |